Sign In
Buy GEHC
$68.02
-1.92 (-2.75%)
At Close: Jul 31, 2026
GE HealthCare Stock Rises. Why Earnings Were a Relief.
07:03am, Wednesday, 04'th Feb 2026
Wednesday, GE HealthCare reported fourth-quarter earnings per share of $1.44 from sales of $5.7 billion. Wall Street was looking for earnings per share of $1.40 from sales of $5.6 billion.
GE HealthCare Technologies Posts Lower Profit, Despite Higher Revenue
06:46am, Wednesday, 04'th Feb 2026
GE HealthCare Technologies said profit fell in the fourth quarter, despite higher revenue, as the company continues to operate in what Chief Executive Peter Arduini called a dynamic macroeconomic envi
GE HealthCare reports fourth quarter and full year 2025 financial results
06:20am, Wednesday, 04'th Feb 2026
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. GE HealthCare President and CEO Peter Arduini said
GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut
02:16pm, Tuesday, 03'rd Feb 2026
GE HealthCare's Allia Moveo wins FDA and CE clearance, enabling commercialization of a mobile C-arm with AI guidance, compact design and early global installs.
GE HealthCare Stock Before Q4 Earnings: To Buy or Not to Buy?
12:35pm, Tuesday, 03'rd Feb 2026
GEHC heads into fourth-quarter earnings with steady demand and strong product momentum, though tariffs and investments may keep margins in focus.
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
10:40am, Monday, 02'nd Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exploring Analyst Estimates for GE HealthCare (GEHC) Q4 Earnings, Beyond Revenue and EPS
10:16am, Monday, 02'nd Feb 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for GE HealthCare (GEHC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for t
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mob
GE HealthCare Technologies Inc. $GEHC Shares Sold by Bank of New York Mellon Corp
04:22am, Friday, 30'th Jan 2026
Bank of New York Mellon Corp lowered its stake in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 1.9% during the third quarter, according to its most recent Form 13F filing with the SEC.
GE HealthCare Technologies (GEHC) Expected to Announce Earnings on Wednesday
05:16am, Wednesday, 28'th Jan 2026
GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) is expected to release its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect GE HealthCare Technologies to
GE HealthCare Technologies Inc. $GEHC Shares Bought by Anchor Capital Advisors LLC
03:27am, Wednesday, 21'st Jan 2026
Anchor Capital Advisors LLC increased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 9.7% in the undefined quarter, according to the company in its most recent Form 13F fi
Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic
11:56am, Friday, 16'th Jan 2026
/PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the
Weekly Option Windfall: Leading Medical Imaging Giant Offers Attractive Entry
02:35pm, Thursday, 15'th Jan 2026
The rise of GEHC reflects its strong positioning in imaging, patient monitoring, and pharmaceutical diagnostics.
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
11:35am, Thursday, 15'th Jan 2026
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
Sell GE HealthCare Stock, UBS Says. The Risks Aren't Known.
11:09am, Thursday, 15'th Jan 2026
Investors aren't concerned enough about China competition or a generic rival, UBS says.
